Detecting and monitoring trophoblastic disease. New perspectives on measuring human chorionic gonadotropin levels

J Reprod Med. 1994 Mar;39(3):193-200.

Abstract

The human chorionic gonadotropin (hCG) molecules in trophoblastic disease serum and urine samples are more heterogeneous, or degraded, than those in pregnancy samples. HCG immunoassays, particularly some of the new multiantibody sandwich tests, are designed primarily for pregnancy application and do not necessarily detect the degraded molecules found in trophoblastic disease samples. This leads to erroneous results and possibly false diagnoses. Care is needed in choosing the hCG test for monitoring trophoblastic disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Bias
  • Chorionic Gonadotropin / blood*
  • Chorionic Gonadotropin / chemistry
  • Chorionic Gonadotropin / urine*
  • False Positive Reactions
  • Female
  • Humans
  • Immunoassay / methods*
  • Immunoassay / standards
  • Pregnancy
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Time Factors
  • Treatment Outcome
  • Trophoblastic Neoplasms / blood*
  • Trophoblastic Neoplasms / epidemiology
  • Trophoblastic Neoplasms / therapy
  • Trophoblastic Neoplasms / urine*
  • Uterine Neoplasms / blood*
  • Uterine Neoplasms / epidemiology
  • Uterine Neoplasms / therapy
  • Uterine Neoplasms / urine*

Substances

  • Chorionic Gonadotropin